Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Janux Therapeutics, Inc.JANX · Entity 4864 | Chief Medical Officer | January 02, 2026 | January 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Janux Therapeutics, Inc.
Report date January 02, 2026 · Filed January 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,286 |
Ending reported balance
After 2026-01-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-02 · Sale · Disposed 2,714 · Balance 23,286 F1: The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units. Row 2 · 2026-01-02 · Grant · Acquired 29,000 · Balance 52,286 F2: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.65 · Expires 2036-01-01 | Direct | 101,500 |
Reported balance
After 2026-01-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-02 · Grant · Acquired 101,500 · Balance 101,500 F3: 25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units.
F2: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027.
F3: 25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 2, 2026 21:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock option (right to buy) · Derivative | 101,500 | $0.00 Strike: $13.65 | $0.00 |
DisclosureSEC source: 0002050056-26-000002 · form4-01022026_090105.xml · derivative · entry 3 McIver Zachariah · CIK 0002050056 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,500 Underlying: Common Stock · 101,500 shares Expires 2036-01-01 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 21:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantCommon Stock | 29,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002050056-26-000002 · form4-01022026_090105.xml · nonDerivative · entry 2 McIver Zachariah · CIK 0002050056 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,286 F2 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027. Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 21:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 2,714 | $13.73 | $37,263.22 |
DisclosureSEC source: 0002050056-26-000002 · form4-01022026_090105.xml · nonDerivative · entry 1 McIver Zachariah · CIK 0002050056 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,286 F1 · kind: The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 20:10 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock option (right to buy) · Derivative | 91,000 | $0.00 Strike: $53.24 | $0.00 |
DisclosureSEC source: 0001415889-25-000677 · form4-01032025_080111.xml · derivative · entry 2 McIver Zachariah · CIK 0002050056 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,000 Underlying: Common Stock · 91,000 shares Expires 2035-01-01 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 20:10 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantCommon Stock | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000677 · form4-01032025_080111.xml · nonDerivative · entry 1 McIver Zachariah · CIK 0002050056 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.